U.S. markets closed

InVivo Therapeutics Holdings Corp. (NVIV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.1500-0.0500 (-4.17%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.2000
Open1.1700
Bid1.1400 x 3000
Ask1.1600 x 900
Day's Range1.1000 - 1.2199
52 Week Range0.5000 - 6.3200
Volume2,206,361
Avg. Volume6,005,055
Market Cap24.348M
Beta (5Y Monthly)1.70
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine
    Business Wire

    InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine

    InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describing the previously presented complete six-month primary endpoint results from the company's single-arm INSPIRE 1.0 study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), titled "A study of probable benefit of a bioresorbable polymer scaffold for safety and neurological recovery in patients with complete thoracic spinal cord injury: 6-month results from the INSPIRE study."

  • InVivo Therapeutics Announces Closing of $15.0 Million Public Offering
    Business Wire

    InVivo Therapeutics Announces Closing of $15.0 Million Public Offering

    InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $0.80 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering were $15.0 million, before deducting the placement agent fees and offering expenses payable by InVivo Therapeutics.

  • InVivo Therapeutics Announces Pricing of $15.0 Million Public Offering
    Business Wire

    InVivo Therapeutics Announces Pricing of $15.0 Million Public Offering

    InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $ 0.80 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering are expected to be approximately $15.0 million, before deducting the placement agent fees and offering expenses payable by InVivo Therapeutics.